ProSomnus Sleep Technologies is pioneering Smart Sleep Medicine by pairing precision-engineered intraoral medical devices with advanced remote patient monitoring (RPM) and proprietary diagnostic tools to treat obstructive sleep apnea. Its non-invasive oral appliances are designed to deliver continuous nightly clinical insights, driving superior patient adherence and validated outcomes. The products are FDA-cleared, patented, and reimbursed by commercial insurers, Medicare, and TRICARE, giving the company access to over 200 million covered lives. ProSomnus positions itself as a patient-preferred, economical alternative to traditional CPAP therapy, addressing a condition that affects more than one billion people worldwide. Looking ahead, the company plans to launch next-generation sensor-enabled devices, expand its connected sleep platform globally, and conduct comparative clinical studies to reinforce efficacy and cost advantages. Capital from its latest funding will support scaling of infrastructure, further technology development, and rigorous clinical validation efforts.

Total raised

$38M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2026